These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30979789)

  • 21. [Clinical features and therapeutic response of our anti-SRP positive patients with myositis].
    Botos B; Nagy-Vincze M; Dankó K
    Orv Hetil; 2017 Sep; 158(35):1382-1389. PubMed ID: 28847176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.
    Basnayake C; Cash K; Blumbergs P; Limaye V
    Clin Rheumatol; 2015 Feb; 34(2):371-7. PubMed ID: 24337692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C1-inhibitor Deficiency Induces Myositis-like Symptoms Via the Deposition of the Membrane Attack Complex in the Muscle.
    Beck G; Yamashita R; Saeki C; Ogawa T; Shimizu M; Mochizuki H
    Intern Med; 2020 Sep; 59(17):2173-2176. PubMed ID: 32461528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies.
    Akintayo RO; Agbola OF; Adeyemo AW; Adelowo O
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28720599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-SRP auto-antibodies are not specific for myositis: Report of 8 cases.
    Rodríguez-Muguruza S; Lozano-Ramos I; Coll-Canti J; Hernández-Gallego A; Ojanguren I; Martinez-Caceres E; Olive A
    Joint Bone Spine; 2017 Jan; 84(1):103-105. PubMed ID: 27236258
    [No Abstract]   [Full Text] [Related]  

  • 27. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients.
    Suzuki S; Nishikawa A; Kuwana M; Nishimura H; Watanabe Y; Nakahara J; Hayashi YK; Suzuki N; Nishino I
    Orphanet J Rare Dis; 2015 May; 10():61. PubMed ID: 25963141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
    Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
    J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
    Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-SRP myopathy: different entity from myositis].
    Suzuki S
    Rinsho Shinkeigaku; 2012; 52(11):1148-50. PubMed ID: 23196545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report.
    Harris C; Marin J; Beaulieu MC
    BMC Nephrol; 2018 Jun; 19(1):152. PubMed ID: 29954345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.
    López De Padilla CM; Crowson CS; Hein MS; Strausbauch MA; Aggarwal R; Levesque MC; Ascherman DP; Oddis CV; Reed AM
    Clin Exp Rheumatol; 2015; 33(5):655-63. PubMed ID: 26446265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review.
    Srikantharajah D; Lloyd ME; Kiely PDW
    Rheumatol Int; 2022 Feb; 42(2):359-364. PubMed ID: 35006287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myopathy with antibodies to the signal recognition particle: clinical and pathological features.
    Miller T; Al-Lozi MT; Lopate G; Pestronk A
    J Neurol Neurosurg Psychiatry; 2002 Oct; 73(4):420-8. PubMed ID: 12235311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
    Rider LG; Yip AL; Horkayne-Szakaly I; Volochayev R; Shrader JA; Turner ML; Kong HH; Jain MS; Jansen AV; Oddis CV; Fleisher TA; Miller FW
    Clin Exp Rheumatol; 2014; 32(5):689-96. PubMed ID: 25068290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.
    Basharat P; Christopher-Stine L
    Curr Rheumatol Rep; 2015 Dec; 17(12):72. PubMed ID: 26515574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resection of Gastric Cancer Remitted Anti-signal Recognition Particle Myopathy.
    Sehara Y; Tsuchiya K; Nishino I; Sato H; Ando Y
    Intern Med; 2022 Aug; 61(16):2509-2515. PubMed ID: 35110495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dropped-head syndrome due to steroid responsive focal myositis: a case report and review of the literature.
    Kastrup A; Gdynia HJ; Nägele T; Riecker A
    J Neurol Sci; 2008 Apr; 267(1-2):162-5. PubMed ID: 17964603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.